Adrenomed AG   Report issue

For profit Phase 1 Phase 2
Founded: Berlin Germany (2009)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2016
NCT02991508
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

adrecizumab (3 trials)

Drugs in Phase 1 Trials (1)

endotoxin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Shock (Phase 2)

Shock, Septic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2